BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
Bio Essence Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026
- Market cap
- $21.38M
- P/E (TTM)
- 10.5
- Dividend yield
- –
Bio Essence Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Revenue from OEM services | $1.90M | $282.75K | – | – | – | 99.9% | +570.7% |
| Shipping and delivery Income | $1.22K | $3.77K | – | – | – | 0.1% | -67.8% |
| Sales of goods | – | $37.42K | $621.59K | $774.07K | $958.70K | – | – |
| Manufacture service revenue | – | – | – | $113.92K | – | – | – |
| Manufacture service revenue | – | $282.75K | $364.17K | $113.92K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Bio Essence's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.